A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System

• Published in: Clinical epidemiology Vol. 14; pp. 789 - 802
• Main Authors: Shu, Yamin, He, Xucheng, Liu, Yanxin, Wu, Pan, Zhang, Qilin
• Format: Journal Article
• Language: English
• Published: Macclesfield Dove Medical Press Limited 30.06.2022; Taylor & Francis Ltd; Dove; Dove Medical Press
• Subjects: Algorithms; Analysis; Breast cancer; Cancer; Care and treatment; Clinical medicine; Clinical outcomes; Data mining; DNA repair; Drugs; Epidemiology; faers; Folic acid; Leukemia; Marketing; Medical personnel; Monosaccharides; Mutation; Neural networks; olaparib; Oncology, Experimental; Original Research; Ovarian cancer; Pancreatic cancer; parp inhibitor; Patients; Pharmacovigilance; Prostate; Prostate cancer; Sugars; Thrombocytopenia; China

Background: Olaparib, the world's first poly ADP-ribose polymerase (PARP) inhibitor (PARPi), has been approved for treatment of ovarian cancer, breast cancer, pancreatic cancer and prostate cancer by FDA. The current study was to assess olaparib-related adverse events (AEs) of real-world throug...